Sector News

Regeneron continues New York expansion with $800M project, 1,500 jobs

September 13, 2018
Life sciences

Regeneron is supersizing a campus expansion in New York, investing $800 million and adding 1,500 jobs and winning a substantial tax break in the process.

The company will build out its second campus in Rensselaer, New York, adding manufacturing capacity, laboratory space and warehouse facilities and adding 1,500 jobs over the next seven years. The state is chipping in $140 million in incentives to help.

According to a spokeswoman, the first part of the project will include about 350,000 square feet of manufacturing space, 240,000 square feet for offices and labs and a 1,000-space parking garage. The campus is about 130 miles north of its headquarters in Tarrytown, New York.

The expansion is slated to take about seven years. This is a larger version of a previously announced expansion for the drugmaker which made its name with blockbuster eye treatment Eylea, but which has more recently added new-generation cholesterol fighter Praluent and rheumatoid arthritis drug Kevzara, both of which it shares with Sanofi.

“As our number of approved and investigational medicines continues to grow, our need for world-class manufacturing teams and facilities also increases,” CEO Leonard S. Schleifer, M.D., Ph.D., said in a statement.

The company, which will have about 7,000 workers in the state when the build-out is complete, has steadily grown there since it launched as a biotech startup in 1988. At the end of 2016, it announced it would buy its headquarters in Tarrytown so it could control its fate there. It paid $720 million for 150 acres, consisting mainly of office buildings and lab space. But the facility has room to grow, with development rights for more than 500,000 square feet of construction.

It has also rapidly built up a biologics manufacturing site in Ireland. Last year, it said it would invest another $100 million there creating 300 more jobs. The U.S. drugmaker, which now boasts the largest bulk biologics plant in a country that has attracted many large pharma, added a number of manufacturing suites to increase drug substance production capacity.

When Regeneron picked up the 400,000-square-foot former Dell computer plant in Limerick in 2013, short-term plans were to invest between $250 million and $300 million and hire 300 employees. Now it expects to have about 800 employees there by the end of the year, with a total investment of about $750 million.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).